Zijun Y Xu-Monette
Overview
Explore the profile of Zijun Y Xu-Monette including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
101
Citations
3457
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xu-Monette Z, Luo C, Yu L, Li Y, Bhagat G, Tzankov A, et al.
Oncoimmunology
. 2024 Aug;
13(1):2384667.
PMID: 39108501
Deficient (d) DNA mismatch repair (MMR) is a biomarker predictive of better response to PD-1 blockade immunotherapy in solid tumors. dMMR can be caused by mutations in MMR genes or...
2.
Yu T, Xu-Monette Z, Lagoo A, Shuai W, Wang B, Neff J, et al.
Front Immunol
. 2024 Feb;
15:1335689.
PMID: 38348048
Introduction: Our previous studies have demonstrated that tumor-infiltrating lymphocytes (TILs), including normal B cells, T cells, and natural killer (NK) cells, in diffuse large B-cell lymphoma (DLBCL) have a significantly...
3.
Yu T, Xu-Monette Z, Yu L, Li Y, Young K
Cell Death Dis
. 2024 Jan;
15(1):19.
PMID: 38195601
No abstract available.
4.
Yu T, Xu-Monette Z, Yu L, Li Y, Young K
Cell Death Dis
. 2023 Nov;
14(11):771.
PMID: 38007476
Lymphoma is the sixth most common type of cancer worldwide. Under the current treatment standards, patients with lymphoma often fail to respond to treatment or relapse early and require further...
5.
Xu-Monette Z, Li Y, Snyder T, Yu T, Lu T, Tzankov A, et al.
Clin Cancer Res
. 2023 Sep;
29(23):4808-4821.
PMID: 37728879
Purpose: Tumor-infiltrating B lymphocytes (TIL-B) have demonstrated prognostic and predictive significance in solid cancers. In this study, we aimed to distinguish TIL-Bs from malignant B-cells in diffuse large B-cell lymphoma...
6.
Sircar A, Singh S, Xu-Monette Z, Coyle K, Hilton L, Chavdoula E, et al.
Leukemia
. 2023 Aug;
37(10):2094-2106.
PMID: 37598282
Mantle cell lymphoma (MCL) is a lethal hematological malignancy with a median survival of 4 years. Its lethality is mainly attributed to a limited understanding of clinical tumor progression and...
7.
Chung E, Sartori G, Ponzoni M, Cascione L, Priebe V, Xu-Monette Z, et al.
Br J Haematol
. 2023 Aug;
203(2):244-254.
PMID: 37584198
The transcriptional factor ETS1 is upregulated in 25% of diffuse large B cell lymphoma (DLBCL). Here, we studied the role of ETS1 phosphorylation at threonine 38, a marker for ETS1...
8.
Lu T, Zhang J, Xu-Monette Z, Young K
Exp Hematol Oncol
. 2023 Aug;
12(1):72.
PMID: 37580826
Diffuse large B-cell lymphoma (DLBCL) can be cured with standard front-line immunochemotherapy, whereas nearly 30-40% of patients experience refractory or relapse. For several decades, the standard treatment strategy for fit...
9.
Al-Juhaishi T, Wang Y, Milton D, Xu-Monette Z, Jabbour E, Daher M, et al.
Bone Marrow Transplant
. 2023 May;
58(9):1000-1007.
PMID: 37198234
Dual expression of MYC and BCL2 proteins (double-expressor lymphoma [DEL]) as well as cell of origin (COO) are important prognostic factors in patients with diffuse large B-cell lymphoma (DLBCL) after...
10.
Pang Y, Lu T, Xu-Monette Z, Young K
Int J Mol Sci
. 2023 Mar;
24(6).
PMID: 36982568
Lymphoma is a heterogeneous group of diseases that often require their metabolism program to fulfill the demand of cell proliferation. Features of metabolism in lymphoma cells include high glucose uptake,...